Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Abstract LB138: A novel dual-TOP1i ADC targeting NaPi2b designed for high efficacy and tolerability

Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Emma Renard, Lia Kallenberger, Ramona Stark, Patrick Maurhofer, Dragan Grabulovski, Bernd Schlereth, Philipp R. Spycher

Cancer Res (2025) 85 (8_Supplement_2): LB138.

https://doi.org/10.1158/1538-7445.AM2025-LB138

Published: 25 April 2025

View articletitled, Abstract LB138: A novel dual-TOP1i ADC targeting NaPi2b designed for high efficacy and tolerability

Journal Articles

Abstract 7334: Targeting Nectin-4 with a first-in-class triple MMAE/dual TOP1i payload ADC showing synergistic and durable activity across all target expression levels and favorable tolerability

Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Rachael Fay, Lia Kallenberger, Patrick Maurhofer, Ramona Stark, Emma Renard, Roger Santimaria, Dragan Grabulovski, Bernd Schlereth, Philipp R. Spycher

Cancer Res (2025) 85 (8_Supplement_1): 7334.

https://doi.org/10.1158/1538-7445.AM2025-7334

Published: 21 April 2025

View articletitled, Abstract 7334: Targeting Nectin-4 with a first-in-class triple MMAE/dual TOP1i payload ADC showing synergistic and durable activity across all target expression levels and favorable tolerability

Journal Articles

Abstract LB124: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo

Isabella Attinger-Toller, Philipp Probst, Lia Kallenberger, Emma Renard, Romain Bertrand, Rachael Fay, Roger Santimaria, Patrick Maurhofer, Dragan Grabulovski, Bernd Schlereth, Philipp Rene Spycher

Cancer Res (2024) 84 (7_Supplement): LB124.

https://doi.org/10.1158/1538-7445.AM2024-LB124

Published: 05 April 2024

View articletitled, Abstract LB124: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo

Journal Articles

Abstract 2600: Novel dual TOP1i ADC inducing superior tumour growth inhibition at low-drug load vs. trastuzumab deruxtecan

Philipp Spycher, Rachael Fay, Romain Bertrand, Philipp Probst, Ramona Stark, Roger Santimaria, Patrick Maurhofer, Lia Kallenberger, Emma Renard, Bernd Schlereth, Dragan Grabulovski, Isabella Attinger-Toller

Cancer Res (2024) 84 (6_Supplement): 2600.

https://doi.org/10.1158/1538-7445.AM2024-2600

Published: 22 March 2024

View articletitled, Abstract 2600: Novel dual TOP1i ADC inducing superior tumour growth inhibition at low-drug load vs. trastuzumab deruxtecan

Journal Articles

Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Emma Renard, Ramona Stark, Roger Santimaria, Dragan Grabulovski, Bernd Schlereth, Philipp Rene Spycher

Cancer Res (2023) 83 (8_Supplement): LB221.

https://doi.org/10.1158/1538-7445.AM2023-LB221

Published: 14 April 2023

View articletitled, Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

Journal Articles

Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

Isabella Attinger-Toller, Rachael Fay, Romain Bertrand, Philipp Probst, Ramona Stark, Roger Santimaria, Dragan Grabulovski, Bernd Schlereth, Philipp Rene Spycher

Cancer Res (2023) 83 (8_Supplement): LB219.

https://doi.org/10.1158/1538-7445.AM2023-LB219

Published: 14 April 2023

View articletitled, Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

Journal Articles

Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Ramona Stark, Roger Santimaria, Emma Renard, Rachael Fay, Dragan Grabulovski, Bernd Schlereth, Philipp René Spycher

Cancer Res (2022) 82 (12_Supplement): 2910.

https://doi.org/10.1158/1538-7445.AM2022-2910

Published: 15 June 2022

View articletitled, Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

Journal Articles

Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Ramona Stark, Roger Santimaria, Dragan Grabulovski, Bernd Schlereth, Philipp Spycher

Cancer Res (2022) 82 (12_Supplement): LB174.

https://doi.org/10.1158/1538-7445.AM2022-LB174

Published: 15 June 2022

View articletitled, Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

Journal Articles

Abstract 1842: CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity

Philipp René Spycher, Philipp Probst, Romain Bertrand, Ramona Stark, Roger Santimaria, Dragan Grabulovski, Isabella Attinger-Toller

Cancer Res (2021) 81 (13_Supplement): 1842.

https://doi.org/10.1158/1538-7445.AM2021-1842

Published: 01 July 2021

View articletitled, Abstract 1842: CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity

Journal Articles

Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8⁺ T-cell Recognition of a Retroviral Antigen

Philipp Probst, Janine Kopp, Annette Oxenius, Mario P. Colombo, Danilo Ritz, Tim Fugmann, Dario Neri

Cancer Res (2017) 77 (13): 3644–3654.

https://doi.org/10.1158/0008-5472.CAN-16-2946

Published: 02 July 2017

View articletitled, Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB138: A novel dual-TOP1i ADC targeting NaPi2b designed for high efficacy and tolerability

Abstract 7334: Targeting Nectin-4 with a first-in-class triple MMAE/dual TOP1i payload ADC showing synergistic and durable activity across all target expression levels and favorable tolerability

Abstract LB124: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo

Abstract 2600: Novel dual TOP1i ADC inducing superior tumour growth inhibition at low-drug load vs. trastuzumab deruxtecan

Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

Abstract 1842: CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity

Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8⁺ T-cell Recognition of a Retroviral Antigen

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only